| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 80,000 | 2,810 | 6,340 | 19,160 | 8,820 |
| Sales Growth | +2,746.98% | -55.68% | -66.91% | +117.23% | unch |
| Net Income | -9,730 | -97,340 | -109,870 | -80,850 | -70,820 |
| Net Income Growth | +90.00% | +11.40% | -35.89% | -14.16% | +14.34% |
Fulcrum Therapeutics Inc (FULC)
2.83 x 1 3.40 x 1
Post-market by (Cboe BZX)
3.02 -0.09 (-2.89%) 03/26/25 [NASDAQ]
2.83 x 1 3.40 x 1
Post-market 3.02 unch (unch) 16:01 ET
for Wed, Mar 26th, 2025
Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.
Fiscal Year End Date: 12/31